Advanced nanomaterial platforms are being engineered to deliver senolytic compounds directly to arthritic joints, clearing senescent cells while simultaneously reprogramming cellular metabolism and reducing inflammation. These precision-targeted therapies use stimuli-responsive nanocarriers that can penetrate cartilage and release therapeutic cargo specifically where needed, potentially reversing the biological clock of aging joints rather than merely managing pain. This represents a fundamental shift from symptom management to disease modification in osteoarthritis treatment. The convergence of three therapeutic targets—cellular senescence, metabolic dysfunction, and chronic inflammation—through a single nanomedicine platform could transform how we approach joint aging. While promising, these technologies remain largely preclinical, with significant translational barriers including manufacturing scalability, regulatory pathways, and cost considerations. The approach mirrors successful aging interventions in other tissues, suggesting that joints may be more reversible than previously thought. If these nanotherapeutic strategies prove clinically viable, they could offer the first true disease-modifying treatments for osteoarthritis, potentially eliminating the need for joint replacement surgery in many patients while extending healthspan.